Metropolitan Life Insurance CO Akero Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

$281 Million
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$17.76 - $31.18 $4,670 - $8,200	263 Added 8.83%	3,242 $81,000
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $21,624 - $27,431	525 Added 21.39%	2,979 $150,000
Q2 2023 Aug 10, 2023	BUY	$36.89 - $56.88 $17,448 - $26,904	473 Added 23.88%	2,454 $114,000
Q1 2023 May 15, 2023	SELL	$37.27 - $50.24 $6,522 - $8,792	-175 Reduced 8.12%	1,981 $75,000
Q4 2022 Jun 14, 2023	BUY	$33.44 - $54.8 $5,852 - $9,590	175 Added 8.83%	2,156 $118 Million
Q4 2022 Mar 30, 2023	BUY	$33.44 - $54.8 $12,707 - $20,824	380 Added 21.4%	2,156 $118,000
Q4 2022 Feb 15, 2023	BUY	$33.44 - $54.8 $12,707 - $20,824	380 Added 21.4%	2,156 $118,000
Q3 2022 Jun 14, 2023	SELL	$10.15 - $34.05 $2,080 - $6,980	-205 Reduced 10.35%	1,776 $60.5 Million
Q2 2022 Jun 20, 2023	SELL	$8.0 - $15.01 $1,640 - $3,077	-205 Reduced 10.35%	1,776 $16,000
Q1 2022 Jun 20, 2023	SELL	$12.97 - $22.26 $2,658 - $4,563	-205 Reduced 10.35%	1,776 $25,000
Q1 2022 Mar 30, 2023	SELL	$12.97 - $22.26 $74,577 - $127,995	-5,750 Reduced 76.4%	1,776 $25,000
Q1 2022 May 12, 2022	SELL	$12.97 - $22.26 $74,577 - $127,995	-5,750 Reduced 76.4%	1,776 $25,000
Q4 2021 Jun 21, 2023	BUY	$19.87 - $26.24 $110,179 - $145,500	5,545 Added 279.91%	7,526 $159,000
Q3 2021 Jun 21, 2023	BUY	$18.65 - $25.46 $103,414 - $141,175	5,545 Added 279.91%	7,526 $168,000
Q2 2021 Jun 21, 2023	BUY	$24.81 - $32.35 $137,571 - $179,380	5,545 Added 279.91%	7,526 $186,000
Q2 2021 Mar 30, 2023	BUY	$24.81 - $32.35 $90,953 - $118,595	3,666 Added 94.97%	7,526 $186,000
Q2 2021 Aug 16, 2021	BUY	$24.81 - $32.35 $186,620 - $243,336	7,522 Added 188050.0%	7,526 $187,000
Q1 2021 Jun 26, 2023	BUY	$24.04 - $34.19 $45,171 - $64,243	1,879 Added 94.85%	3,860 $112 Million
Q1 2021 May 14, 2021	SELL	$24.04 - $34.19 $92,698 - $131,836	-3,856 Reduced 99.9%	4 $112,000
Q4 2020 Jun 22, 2023	BUY	$25.12 - $29.89 $47,200 - $56,163	1,879 Added 94.85%	3,860 $99,000
Q3 2020 Jun 26, 2023	BUY	$30.79 - $39.92 $57,854 - $75,009	1,879 Added 94.85%	3,860 $118,000
Q2 2020 Jun 26, 2023	BUY	$19.25 - $26.76 $36,170 - $50,282	1,879 Added 94.85%	3,860 $96,000
Q2 2020 Mar 30, 2023	BUY	$19.25 - $26.76 $32,802 - $45,599	1,704 Added 79.04%	3,860 $96,000
Q2 2020 Aug 14, 2020	BUY	$19.25 - $26.76 $74,305 - $103,293	3,860 New	3,860 $96,000

Others Institutions Holding AKRO

# of Institutions

193

Shares Held

74.6M

Call Options Held

241K

Put Options Held

647K

Wellington Management Group LLP Boston, MA

7.9M
Shares

$445 Million
0.04% of portfolio
Janus Henderson Group PLC London, X0

7.08M
Shares

$399 Million
0.11% of portfolio
Rtw Investments, LP New York, NY

5.92M
Shares

$334 Million
2.71% of portfolio
Black Rock Inc. New York, NY

5.59M
Shares

$315 Million
0.0% of portfolio
General Atlantic LLC New York, NY

5.23M
Shares

$295 Million
4.29% of portfolio

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.62B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account